Stock AnalizEnovis CORP ENOV
Industrial Specialties · data as of November 13, 2026
Enovis CORP (ENOV) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to October 2, 2026 it had revenue of $2.3B and net income of -$527M, a net margin of -22.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 23.0, 5-year revenue growth of 15% a year, a 5-year average ROIC of -10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 26% below the current price.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.2B | $2.1B | $1.7B | $1.6B | $1.4B | $1.1B | $3.3B | $3.7B | $3.3B | $3.2B |
| Net income | -$527M | -$1.2B | -$825M | -$33M | -$13M | $72M | $43M | -$528M | $140M | $151M | $128M |
| Free cash flow | $70M | $20M | -$67M | $13M | -$161M | $252M | $187M | $6M | $157M | $150M | $184M |
| EPS (diluted) | $-9.22 | $-20.75 | $-14.93 | $-0.61 | $-0.25 | $1.40 | $0.93 | $-11.85 | $3.53 | $3.72 | $3.17 |
| Net margin | -22.9% | -52.7% | -39.2% | -1.9% | -0.9% | 5.0% | 3.8% | -15.9% | 3.8% | 4.6% | 4.0% |
| ROIC | — | -30.9% | -15.4% | -1.3% | -1.5% | -0.8% | -0.7% | 2.7% | 2.7% | 2.8% | 4.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $37.83, 37% above the current price; targets range from $27.00 to $47.00; the consensus rating is “Strong buy”; expected EPS is $3.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Enovis CORP stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 26% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Enovis CORP pay a dividend?
Not currently.
Is Enovis CORP a good stock to buy?
We do not give buy or sell advice. Enovis CORP scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.